Boardroom Alpha
Meeting calendar
INCY · Annual meeting · Monday, June 8, 2026

Incyte Corp

9 nominees · 3 ballot items.

Elect eight directors; advisory vote to approve named executive officer compensation (say-on-pay); ratify Ernst & Young LLP as independent registered public accounting firm.

Market cap
$23.3B
1Y TSR
+58.6%
Board grade
C-
Record date
Apr 14, 2026
Filing
DEF 14A
Meeting concluded · Jun 8, 2026

Follow how the vote landed and what changed on Incyte Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect eight directors to serve until the 2027 annual meeting and until their successors are duly elected and qualified.

  2. 2

    Advisory Vote to Approve Executive Compensation

    ManagementBoard: FOR

    Non-binding, advisory vote to approve compensation of the company’s named executive officers as disclosed in the proxy statement (say-on-pay).

    More detail

    This management proposal asks shareholders to cast a non-binding advisory vote to approve the compensation of Incyte’s named executive officers as disclosed in the proxy statement. Management seeks shareholder approval to validate its executive pay program, which emphasizes pay-for-performance through a mix of base salary, annual cash incentives and equity-based awards (performance shares, options and RSUs). The compensation program is presented as designed to attract and retain senior leadership during a pivotal period of pipeline advancement and commercial expansion, aligning incentives with long-term shareholder value through multi-year performance share vesting (TSR-relative metrics) and time-based awards. The Compensation Committee, composed entirely of independent directors, recommends a FOR vote and justifies it by pointing to market benchmarking, use of independent consultants, clawback policies, equity ownership guidelines, and the large proportion of at-risk compensation. The proxy discloses significant one-time sign-on and inducement awards for the CEO and other executives, robust severance/change-in-control protections, and mechanisms that may accelerate vesting in certain events — aspects that some investors may scrutinize. Given the extensive disclosure of target pay, performance metrics, governance controls, and rationale, management frames the advisory vote as an endorsement of the overall compensation framework and its implementation in 2025.

  3. 3

    Ratification of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Director elections

Nominees on the ballot9

Independent
Tenure on this board
24.6 yrs
Also a director at
Acadia Pharmaceuticals Inc (ACAD)Madrigal Pharmaceuticals Inc (MDGL)Denali Therapeutics Inc (DNLI)
Independent
Tenure on this board
11.5 yrs
Also a director at
Immunome Inc (IMNM)Keros Therapeutics Inc (KROS)Ascendis Pharma A (ASND)
Independent
Tenure on this board
4.8 yrs
Also a director at
Pds Biotechnology Corp (PDSB)Lyell Immunopharma Inc (LYEL)Agilent Technologies Inc (A)
Independent
Tenure on this board
11.5 yrs
Also a director at
Sionna Therapeutics Inc (SION)
Independent
Tenure on this board
8.7 yrs
Also a director at
Agios Pharmaceuticals Inc (AGIO)Madrigal Pharmaceuticals Inc (MDGL)
Independent
Tenure on this board
3.5 yrs
Also a director at
Biontech Se (BNTX)
Ownership

Top institutional holders10

Latest 13F quarter
1BAKER BROS. ADVISORS LP15.4%30,744,412$2.9B
2DODGE COX6.1%12,252,356$1.2B
3VANGUARD CAPITAL MANAGEMENT LLC5.5%10,930,066$1.0B
4STATE STREET CORP4.8%9,641,384$907M
5BlackRock, Inc.4.2%8,428,716$793M
6VANGUARD PORTFOLIO MANAGEMENT LLC3.9%7,759,183$730M
7AQR CAPITAL MANAGEMENT LLC2.8%5,647,816$521M
8GEODE CAPITAL MANAGEMENT, LLC2.1%4,153,612$389M
9LSV ASSET MANAGEMENT2.0%3,920,056$369M
10BlackRock, Inc.1.9%3,850,954$362M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Incyte Corp 2026 annual meeting?
Incyte Corp (INCY) holds its 2026 annual shareholder meeting on Monday, June 8, 2026.
What is the record date for the Incyte Corp 2026 meeting?
The record date for the Incyte Corp 2026 meeting is Tuesday, April 14, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Incyte Corp's 2026 meeting?
The board is presenting 9 director nominees at the Incyte Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Incyte Corp 2026 meeting?
Shareholders will vote on 3 proposals at the Incyte Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer